Lemborexant (Dayvigo)

Key Messages

• CADTH recommends that Dayvigo not be reimbursed by public drug plans for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
• Two clinical trials showed that, compared to placebo, Dayvigo resulted in improvements in the time it takes to fall asleep, the time spent awake after initially falling asleep, and the time spent sleeping divided by the total time spent in bed measured during sleep studies.
• It was uncertain whether the effect of Dayvigo was enough to make a clinically meaningful improvement for the sleep outcomes measured using patients’ sleep diaries.
• Based on the evidence reviewed, it is uncertain whether Dayvigo offers a meaningful clinical benefit over other treatments used for insomnia. There was not enough evidence to conclude that Dayvigo meets patients’ needs for a treatment with long-term effectiveness that results in uninterrupted and restorative sleep, less stress and anxiety, improved productivity, improved relationships, and fewer side effects compared to other treatments for insomnia. It was also unclear if patients receiving Dayvigo would be able to manage their sleep problems without becoming dependent on the medication.